FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).
about
Recent developments in receptor tyrosine kinases targeted anticancer therapyFibroblast growth factor receptor signaling as therapeutic targets in gastric cancerFunctional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancersPreclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR DysregulationFGF receptors: cancer biology and therapeuticsGrb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancermiR-381-3p suppresses the proliferation of oral squamous cell carcinoma cells by directly targeting FGFR2.Linked read sequencing resolves complex genomic rearrangements in gastric cancer metastases.Palifermin for the protection and regeneration of epithelial tissues following injury: new findings in basic research and pre-clinical models.Potential prognostic and diagnostic application of a novel monoclonal antibody against keratinocyte growth factor receptor.TNFα modulates Fibroblast Growth Factor Receptor 2 gene expression through the pRB/E2F1 pathway: identification of a non-canonical E2F binding motif.D-glucuronyl C5-epimerase suppresses small-cell lung cancer cell proliferation in vitro and tumour growth in vivo.Signaling mechanisms of the epithelial-mesenchymal transition.Pathway Regulation of p63, a Director of Epithelial Cell FateStimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines.Pin1 Inhibitor Juglone Exerts Anti-Oncogenic Effects on LNCaP and DU145 Cells despite the Patterns of Gene Regulation by Pin1 Differing between These Cell Lines.Inhibition of fibroblast growth factor receptor 2 attenuates proliferation and invasion of pancreatic cancerA comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.Model systems for studying trophoblast differentiation from human pluripotent stem cells.Long noncoding RNA papillary thyroid carcinoma susceptibility candidate 3 (PTCSC3) inhibits proliferation and invasion of glioma cells by suppressing the Wnt/β-catenin signaling pathway.The genetics of breast cancer: risk factors for disease.The anti-apoptotic and prognostic value of fibroblast growth factor 9 in gastric cancer.Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models.Altered expression of fibroblast growth factor receptor 2 isoform IIIc: relevance to endometrioid adenocarcinoma carcinogenesis and histological differentiation.Binding of human recombinant mutant soluble ectodomain of FGFR2IIIc to c subtype of FGFRs: implications for anticancer activity.Fibroblast growth factor receptor 2: a therapeutic target in gastric cancer.Quantitative and Sensitive Detection of Cancer Genome Amplifications from Formalin Fixed Paraffin Embedded Tumors with Droplet Digital PCR.Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT-SSX2.Alternative Splicing of Fibroblast Growth Factor Receptor IgIII Loops in Cancer.A multiplex preclinical model for adenoid cystic carcinoma of the salivary gland identifies regorafenib as a potential therapeutic drug.The RNA-binding protein ESRP1 promotes human colorectal cancer progression.Effects of leukemia inhibitory factor and basic fibroblast growth factor on free radicals and endogenous stem cell proliferation in a mouse model of cerebral infarction.Fibroblast growth factor receptor 2: expression, roles, and potential as a novel molecular target for colorectal cancer.Epigenetic control of epithelial-mesenchymal-transition in human cancer.MicroRNA-338-3p regulates osteogenic differentiation of mouse bone marrow stromal stem cells by targeting Runx2 and Fgfr2.The influence of neural cell adhesion molecule isoform 140 on the metastasis of thyroid carcinoma.Paracrine Fibroblast Growth Factor Initiates Oncogenic Synergy with Epithelial FGFR/Src Transformation in Prostate Tumor Progression.Molecular signatures classify astrocytic gliomas by IDH1 mutation status.DEAD-Box Protein RNA-Helicase DDX6 Regulates the Expression of HER2 and FGFR2 at the Post-Transcriptional Step in Gastric Cancer Cells
P2860
Q26751331-A979E308-2459-4F94-A605-86E948C6E1A6Q26764932-8ACA330B-215D-4D0F-A95B-5763DD40ABD2Q26998955-46173875-D8AC-45B4-95B5-E47702F34304Q27322795-681B5F2D-97B2-4219-86A0-051F364945CBQ28291186-722DC27F-3108-4664-A474-CD162714682AQ28389726-FAC46084-FDAF-4AD1-8F38-F9BEEA286F2EQ33622684-2B2295FC-5B0E-4F55-A123-440B5E95AB00Q33815218-1A26DA43-1727-4317-8C9B-1EFEBB085A4EQ33985578-D7422D3F-1A6C-43F9-83D9-C65113AE9E31Q34136499-A68A025A-8CD9-4C17-AD38-651C4DDAAA00Q34684477-C806ACA2-3024-4726-AB25-2C8BE9E63D3BQ35108319-55CF9E6A-939B-4A80-9B01-5A022BD258CBQ35213019-71764397-F7A6-4AFB-ABD1-D94FE3A54B26Q35545782-C6DF053F-21F6-4BED-B5C8-644B088E0259Q35610049-DAA2392A-71BA-4232-B23A-D1A8F7BEDD3AQ35650902-8BB4E94A-DABD-493A-A79E-BB1069E42CFEQ35713603-D3B4F912-735A-4DCA-A98B-E17BD73E4EBAQ35878807-E6CFFF9A-C7BB-4DC7-A3E3-DD02F7352B3DQ36195420-D9B99483-24AC-434F-A8A9-DCB053A97A8FQ36277413-450ECB3D-F205-4DF8-92ED-CA1CCA7AC19FQ36925187-673D44AE-371D-4A8F-B1DB-E2805E769EFAQ37392801-58504CE0-8758-4E55-9F4D-4F66FAE911DAQ37507462-F9787FAB-6BE4-4FC1-B341-01034394C238Q37676762-A0CBD838-4E27-4EEB-A4AD-C32A07DB01E6Q37708821-35DBFDD5-4B85-4D17-A150-4C7535A7A171Q38153418-84598096-D8A2-4EC2-BC5A-7B66F7D6FBB3Q38406148-96B300ED-0DA8-44FC-B1C0-C8785FD653ADQ39458600-D59B93B7-D7B1-410B-867C-20674EEA6060Q39803624-BF2B8B0D-CFC7-4B41-ABC1-D228F098FB43Q41194627-20A8CEBC-1F53-4D61-880E-BFA41CE48D4EQ41835902-F36D7A8C-44CA-4332-BF40-C50778C44755Q42010368-8E545AFA-9469-4FAA-A4EC-92336AACA486Q42198612-E7886244-D17A-42ED-80B7-D7E5EA2CF92BQ42409031-0FF4F919-9DD7-46D3-B574-18856CC504F9Q44000706-911D0848-B60B-4E72-81F6-14D902CF9FDDQ48605433-805DE9C4-068D-4945-BDB5-9BA8F0F2DEB0Q49997063-9D10E4E1-277A-42C3-BA74-B652C3FDE199Q54673894-E9FA1E63-DBB0-4A64-AC06-86B1FA3A0733Q57753663-51B48EB0-4623-473C-9D51-9399E13482D1
P2860
FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).
@en
FGFR2-related pathogenesis and FGFR2-targeted therapeutics
@nl
type
label
FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).
@en
FGFR2-related pathogenesis and FGFR2-targeted therapeutics
@nl
prefLabel
FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).
@en
FGFR2-related pathogenesis and FGFR2-targeted therapeutics
@nl
P356
P1476
FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).
@en
P2093
Masaru Katoh
Yuriko Katoh
P304
P356
10.3892/IJMM_00000132
P577
2009-03-01T00:00:00Z